Compare Enveric Biosciences Inc (ENVB) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs TotalEnergies SE — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while TotalEnergies SE trades at $86.07 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 28672.6× Enveric Biosciences Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and TotalEnergies SE for 90 Days on average.
| ENVB | TTE | |
|---|---|---|
Market Cap | $6.69M | $191.82B |
Volume | 41,141 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $10.80 | $93.60 |
52-Week Low | $1.27 | $57.39 |
Typical Hold Time | 14 Days | 90 Days |
Enterprise Value | -$1.60M | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 10.54 and P/S of 0.94. Recent earnings beat expectations in Q1 and Q2 2026, though revenue has declined from 2022 peaks. The company maintains a strong cash flow profile and has announced a $10 billion investment in Argentina, alongside a commitment to grow dividends by 5% annually through 2030.
The outlook is supported by strategic expansions in LNG and power, but risks include volatile energy prices and execution of capital projects. Analyst consensus is bullish with a $95.33 price target, implying potential upside. Investors should weigh the company's solid fundamentals and shareholder returns against sector-specific headwinds and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
